Alphamab Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Suzhou China (2009)

Organization Overview

First Clinical Trial
2017
NCT03101488
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Alphamab (Australia) Co Pty Ltd. | Alphamab Jilin Co., Ltd. | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Suzhou Alphamab Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 2)

Digestive System Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Infertility (Phase 1)

Infertility, Female (Phase 1)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 1)

Neoplasms (Phase 2)

Stomach Neoplasms (Phase 1)

Thymoma (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 32
  • # of Trial APIs: 26